Healthcare provisions in the Inflation Reduction Act
What’s changing for Medicare plans, pharmaceutical manufacturers, and other healthcare stakeholders?
An overview of the new healthcare regulations
Article
The Inflation Reduction Act's key reforms
Get an overview of the law's main changes to Medicare and other healthcare markets, and a timeline for implementation.
Read the articleWEBINAR
The Inflation Reduction Act's key reforms
Get an overview of the law's main changes to Medicare and other healthcare markets, and a timeline for implementation.
Watch the webinarWHITE PAPER
Lessons from the first drugs chosen for Medicare price negotiation
The Inflation Reduction Act requires drug manufacturers to negotiate prices with the federal government, a change with wide-ranging implications for the pharmaceutical industry and healthcare payers.
View the paper
Insight
The evolution of biosimilars in the United States
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
Out of whose pocket? Many beneficiaries will spend less than expected to reach the IRA’s new $2,000 out-of-pocket spending limit
We dive into ramifications of the Inflation Reduction Act on out-of-pocket spending limits for health insurance markets and Medicare Part D.
Navigating new waters: How the Inflation Reduction Act alters government funding for Medicare Part D
The 2025 national average Part D direct subsidy (DS) will increase to $142.67 as plan sponsors take on additional Part D risk in 2025.
A prescription for change: How the 2025 Medicare Part D risk adjustment (RxHCC) model overhaul will affect risk scores
Medicare Advantage organizations (MAOs) will experience another material model change in 2025—this time for Part D.
Impact of the Inflation Reduction Act on plans seeking creditable coverage
Plan sponsors seeking creditable coverage for their retiree prescription drug plans may need to enrich coverage in 2025, due to effects from the Inflation Reduction Act (IRA).
Stakeholder perspectives on the transformative IRA Part D benefit redesign
We discuss how the Inflation Reduction Act could affect Medicare Part D plans, members, the government, and pharmaceutical manufacturers.
Financial implications from the Medicare Part D redesign and new maximum out-of-pocket amount
We examine potential ramifications of the Inflation Reduction Act, which may drive the biggest changes in prescription drug coverage since Medicare Part D.
Medicare Prescription Payment Plan: What plan sponsors need to know
Understanding how the IRA lets beneficiaries smooth their cost sharing over the plan year.
How might the IRA affect Medicare Part D prescription drug rebates?
We offer a primer on the Medicare Part D prescription drug rebates, with insights into the possible impact of the Inflation Reduction Act.
Preparing for the next Medicare bid cycle
Related Milliman services
Recommended for you
Milliman MACVAT (Medicare Advantage Competitive Value Added Tool)
